Block Listing Six Monthly Return

Alliance Pharma PLC

02 January 2024

 

For immediate release

02 January 2024

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)     The Alliance Pharma plc Approved Share Option Plan 2005 b)    The Alliance Pharma plc Share Option Plan 2006 c)     The Alliance Pharma plc Company Share Option Plan 2015 d)    The Alliance Pharma plc Long-Term Incentive Plan 2019
Period of return:	From:	28 June 2023	To:	31 December 2023
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)     57,922 b)    2,487,746 c)     9,572,622 d)    1,341,116
Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)     Nil b)    Nil c)     Nil d)    Nil
Less:  Number of securities issued/allotted under schemes during period:		a)  0 b) 14,239 c)  0 d) 225,618
Equals:  Balance under schemes not yet issued/allotted at end of period:		a)    57,922 b)    2,473,507 c)     9,572,622 d)    1,115,498

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Head of Investor Relations: Cora McCallum	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills
[e-mail]
Deutsche Numis (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END